Stockscreener 앱 받기
12.25
1.85%
-0.20
시간 외 거래:
12.25
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
Jefferies cuts Kalvista stock price target to $31 from $33 By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Advances Sebetralstat for HAE - TipRanks
KalVista Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Kalvista Pharmaceuticals Inc reports results for the quarter ended January 31Earnings Summary - TradingView
KALVISTA PHARMACEUTICALS Earnings Results: $KALV Reports Quarterly Earnings - Nasdaq
KalVista's Oral HAE Treatment Delivers 76-Minute Relief as FDA Review Nears - StockTitan
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - The Bakersfield Californian
Reviewing KalVista Pharmaceuticals (NASDAQ:KALV) and Hillstream BioPharma (NASDAQ:HILS) - Defense World
KalVista Pharmaceuticals CEO sells $79,827 in stock By Investing.com - Investing.com Australia
KalVista Pharmaceuticals CEO sells $79,827 in stock - Investing.com
KalVista Pharmaceuticals CEO Sells Shares to Cover Tax Obligations - TradingView
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema - The Bakersfield Californian
KalVista to Present Commercial Strategy for New HAE Treatment Sebetralstat - StockTitan
Kalvista Pharmaceuticals Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
JMP Securities sets $19 target for Kalvista Pharmaceuticals stock - MSN
JMP reiterates Kalvista stock with $19 target, sees market growth - MSN
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Joplin Globe
KalVista Issues 14,000 Share Options to New HiresWhat This Means for KALV Investors - StockTitan
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting - BioSpace
Sebetralstat shows promise in treating HAE attacks By Investing.com - Investing.com Canada
Sebetralstat shows promise in treating HAE attacks - Investing.com India
KalVista stock holds firm with $19 target from JMP - Investing.com India
KalVista stock holds firm with $19 target from JMP By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals (KALV) to Release Quarterly Earnings on Monday - Defense World
Revolutionary Oral HAE Treatment From KalVista Achieves 96% Effectiveness in Minutes - StockTitan
KalVista Pharmaceuticals’ Sebetralstat: A Game-Changer in Oral HAE Treatment with Strong Market Potential - TipRanks
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Buy" from Brokerages - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 2,394 Shares - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $23.80 Average Price Target from Brokerages - Defense World
KalVista Pharmaceuticals’ chief development officer sells $19,218 in stock - Investing.com India
KalVista Pharmaceuticals CMO Audhya Paul sells $23,987 in stock - Investing.com India
KalVista Pharmaceuticals CMO Audhya Paul sells $23,987 in stock By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals’ chief development officer sells $19,218 in stock By Investing.com - Investing.com UK
KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - The Bakersfield Californian
Can KalVista's March Conference Circuit Signal Major Pipeline Updates? - StockTitan
Insider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells 3,125 Shares of Stock - MarketBeat
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting - Business Wire
Can This New Oral Drug Transform HAE Treatment? Key Clinical Data Revealed - StockTitan
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 5,104 Shares - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 8.7%What's Next? - MarketBeat
KalVista Pharmaceuticals chief medical officer sells $30,700 in stock By Investing.com - Investing.com Canada
KalVista Pharmaceuticals CEO sells $50,142 in stock - Investing.com India
KalVista Pharmaceuticals chief medical officer sells $30,700 in stock - Investing.com India
KalVista Pharmaceuticals chief development officer sells shares for $25,552 - Investing.com India
KalVista Pharmaceuticals CEO sells $50,142 in stock By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals chief development officer sells shares for $25,552 By Investing.com - Investing.com Nigeria
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - Defense World
Japan grants orphan drug status to HAE treatment - MSN
0.49%
1.87%
자본화:
|
볼륨(24시간):